Eledon Pharmaceuticals Announces Updated Data from Phase 1b Trial of Tegoprubart for Kidney Transplant Rejection Prevention at World Transplant Congress 2025

Reuters
18 Jul
Eledon Pharmaceuticals Announces Updated Data from Phase 1b Trial of Tegoprubart for Kidney Transplant Rejection Prevention at World Transplant Congress 2025

Eledon Pharmaceuticals Inc. has announced that updated clinical data from its ongoing Phase 1b trial of tegoprubart, an anti-CD40L antibody, will be presented at the upcoming World Transplant Congress 2025 in San Francisco. The open-label study focuses on the prevention of rejection in patients undergoing kidney transplantation. The oral presentation, scheduled for August 6, 2025, will feature results from approximately 30 kidney transplant recipients and will be delivered by Dr. John Gill from the University of British Columbia. The presentation will be part of the session on "Kidney Novel Immunosuppressant Strategies." Additionally, Eledon will sponsor a satellite symposium at the congress and present new preclinical data on tegoprubart in a poster session. A copy of the oral presentation will be available on the company's website following the session.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eledon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9496487-en) on July 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10